Getting started with KYMBEE™ Below you’ll find tips for talking with your healthcare provider and a step-by-step look at how getting started works. Before you begin Starting a new treatment can feel like a big step—but you don’t have to figure it out alone. If you’re considering a change to your child’s treatment, talk to their healthcare provider to see whether KYMBEE may be the right choice. Talking with your healthcare provider about KYMBEE Tips for starting the conversation If you’re considering a switch or just want to learn more about KYMBEE for the treatment of Duchenne muscular dystrophy (DMD) in patients 5 years of age and older, here are a few ways to prepare for your next appointment: Write down your questions Think about what matters most to you. For example, How does deflazacort work? What role do patient support programs play? Could KYMBEE be right for my child’s care plan? Bring recent treatment information Sharing which medications your child is currently taking and how they’ve responded can help your provider offer guidance that’s specific to your child. Ask about the Promise of Support® Program Your provider or clinical team can explain how enrollment works and connect you with a Patient Care Coordinator for help getting started. Take notes and, when possible, bring a friend or loved one Appointments can move quickly. Writing things down—or having a trusted friend listen along—can help you remember important details. Your provider or clinical team can also explain how the Upsher‑Smith Promise of Support® Program helps families get started smoothly—from answering questions and managing insurance to coordinating delivery and ongoing care. Here’s how the Promise of Support® Program works We manage almost every part of the process for you—from insurance navigation to delivery—so your role is intended to be minimal. You’ll only need to answer a quick call and confirm your refill schedule. Your step-by-step guide to the process: Promise of Support® Program action Caregiver action Prescription receivedYour child’s healthcare provider or clinical team sends the prescription to Orsini. Patient enrollmentWithin 24 hours, any needed information from your child’s provider is collected and enrollment is completed. Insurance coverageInsurance is checked and requests are made for prior authorization if needed. Pharmacist reviewA pharmacist reviews the prescription and contacts your child’s provider if needed. Caregiver callAfter pharmacist review, you will be called to discuss available patient support and schedule medication shipment. Medication deliveryYour child’s medication ships overnight. Refill coordinationYou will be contacted 7–10 days before each refill to schedule shipment. Ready to get started with KYMBEE and see how our Promise of Support® Program can help? Discover how your Care Team aims to simplify coverage, coordinate delivery, and help your child start—and stay—on deflazacort therapy. Savings and support Resources Explore FAQs Request to stay informed IMPORTANT SAFETY INFORMATION & INDICATION for KYMBEE™ (deflazacort) Tablets Who should not take KYMBEE? Do not take if you have had hypersensitivity, including allergic reactions, to deflazacort (the active ingredient in KYMBEE) or to any of the inactive ingredients in KYMBEE. What is the most important information I should know about KYMBEE? KYMBEE can cause changes in endocrine (hormone) function. Do not stop taking KYMBEE, or change the amount being taken, without first checking with a healthcare provider, as there may be a need for gradual dose reduction to decrease the risk of adrenal insufficiency and steroid “withdrawal syndrome.” Acute adrenal insufficiency can occur if corticosteroids, including KYMBEE, are withdrawn abruptly, and can be life threatening. A steroid “withdrawal syndrome” may also occur following abrupt discontinuance of corticosteroids. For patients already taking corticosteroids during times of stress, the amount of KYMBEE prescribed may need to be increased. There is an increased risk of infection when taking KYMBEE. Tell a healthcare provider if the patient has had recent or ongoing infections or if they have recently received a vaccine. Seek medical advice immediately if the patient develops fever or other signs of infection. Some infections can potentially be severe and life threatening. Patients should avoid exposure to chickenpox or measles and alert their healthcare provider immediately if they are exposed. KYMBEE can cause an increase in blood pressure and water retention. If this occurs, dietary salt restriction and potassium therapy may be needed. There is an increased risk of developing a hole in the stomach or intestines in patients with certain gastrointestinal disorders when taking corticosteroids like KYMBEE. KYMBEE can cause behavior and mood changes that can be severe. Seek medical attention if any behavioral or mood changes develop. There is a risk of osteoporosis with prolonged use of KYMBEE, which can lead to fractures in the spine and in long bones. KYMBEE may cause cataracts or glaucoma. A healthcare provider should monitor for these conditions if therapy is continued for more than 6 weeks. Immunizations should be up-to-date according to immunization guidelines prior to starting therapy with KYMBEE. Live attenuated or live vaccines should be administered at least 4 to 6 weeks prior to starting KYMBEE. Live attenuated or live vaccines should not be used in patients taking KYMBEE. KYMBEE can cause serious skin rashes. Seek medical attention at the first sign of a rash. Rare instances of anaphylaxis, a severe allergic reaction, have occurred in patients receiving corticosteroid therapy, including KYMBEE. Before taking KYMBEE, tell a healthcare provider about all medical conditions, including if the patient: is pregnant or planning to become pregnant. KYMBEE can harm an unborn baby. is breastfeeding or planning to breastfeed. KYMBEE may appear in breastmilk and could affect a nursing child. Certain medications can cause an interaction with KYMBEE. Tell a healthcare provider about all the medicines you are taking, including over-the-counter medicines (such as insulin, aspirin or other non-steroidal anti-inflammatory drugs), dietary supplements, and herbal products. Alternate treatment, dosage adjustment, and/or special test(s) may be needed during the treatment. What are the side effects of KYMBEE? The most common side effects include: facial puffiness or Cushingoid appearance, weight increased, increased appetite, upper respiratory tract infection, cough, frequent daytime urination, unwanted hair growth, abdominal obesity, and colds. These are not all of the possible side effects. Call a healthcare provider for medical advice about side effects. This safety information is not comprehensive. Please see the full Prescribing Information for more information on KYMBEE. You can also visit www.upsher-smith.com or call 1-888-650-3789. You are encouraged to report suspected adverse reactions to the FDA by visiting www.fda.gov/medwatch or by calling 1-800-FDA-1088. What is KYMBEE? KYMBEE (deflazacort) Tablets are a prescription medicine used to treat Duchenne muscular dystrophy (DMD) in patients 5 years of age and older.